Table 1. Published series reporting Snellen visual acuity in eyes with retinoblastoma.
Included series were published 2006 or later (concurrent with our study population), listed in order of cohort size (RE = Reese-Ellsworth classification).
| Authors | Publication | Primary treatment | Number of eyes | Classification | Enucleation | % 20/40 or greater | % 20/50 to 150 | % Poor vision | Fix/Follow | Follow-up (months) |
| Levin et al | (present) | OAC | 157 | ICRb D or E | 39 (25%) | 19 (12%) | 5 (3%) | 133 (85%, 20/200 or worse) | NA | 51 |
| Levin et al | (present) | OAC | 63 | Unilateral ICRb D or E with macular disease | 11 (17%) | 4 (6.3%) | 1 (1.5%) | 58 (92%) | NA | |
| Levin et al | (present) | OAC | 18 | Unilateral ICRb D or E with no macular disease | 4 (22%) | 5 (28%) | 1 (5.6%) | 12 (67%) | NA | |
| Berry et al | Pediatr Blood Cancer. 2013 Apr;60(4):688–93. | IVC plus EBR | 62 | ICRb D | 17 (27%), included | 5 (8.1%) | 6 (8.3%) | 31 (50%, 20/200 or worse) | 20 (32%) | 54.2 |
| Berry et al | Br J Ophthalmol. 2014 Aug;98(8):1061–5. | IVC plus EBR | 52 | ICRb D | Enucleation excluded | 5 (9.6%) | 12 (23%) | 25 (71%; worse than 20/200) | 10 (19%) | 50 |
| Shields et al | Ophthalmology. 2009 Mar;116(3):544-551.e1 | IVC | 38 | ICRb E | Enucleation excluded | 4 eyes (11%, 20/50 or better) | 11 (29%, 20/60 to 20/100) | 21 (55%, 20/200 or worse) | 2 (5.3%) | 63 |
| Choi et al | J Korean Med Sci. 2010 Apr;25(4):546–51. | EBR | 32 | RE II-V | 8 (25%), included | 9 (28%) | 5 (16%) | 18 (56%, 20/200 or worse) | NA | 150 |
| Fabian et al | Am J Ophthalmol. 2017 Jul;179:137–144. | IVC plus adjuvent | 32 | ICRb D | Enucleation excluded | 7 (22%) | 9 (28%) | 16 (50%, worse than 20/200)a | NA | 64.4 |
| Rao et al | Br J Ophthalmol. 2018 Apr;102(4):490–495. | Intravit. injection | 17 | ICRb C and D | 1 (5.8%), included | 6 (35%) | 5 (29%) | 5 (29%, 20/200 or worse) | NA | 23.8 |
| Schefler et al | Ophthalmology. 2007 Jan;114(1):162–9. | IVC and laser | 14 | RE I-V | Enucleation excluded | 5 (36%) | 3 (21%) | 6 (43%, 20/200 or worse) | NA | 36 |
| Authors | Publication | Primary treatment | Number of eyes | Classification | Enucleation | % 20/40 or greater | % 20/50 to 150 | % Poor vision | Fix/Follow | Follow-up (months) |
| Kim et al | Korean J Ophthalmol. 2010 Dec;24(6):347–52. | IVC plus local | 13 | ICRb B | Enucleation excluded | 5 (38%) | 2 (15%) | 6 (46%, 20/200 or worse) | NA | 79.3 |
| Tsimpida | Br J Ophthalmol. 2013 Nov;97(11):1464–70. | IAM | 12 | (excluded eyes with foveolar disease) | 0 (0%) | 6 (50%) | 1 (8.3%) | 4 (33%, 20/200 or worse) | 1 (8.3%) | 21 |
| Jung et al | J Pediatr Hematol Oncol. 2018 Apr 20. | Proton beam rad. | 4 | ICRb D | 2 (50%), included | 1 (25%) | 0 (0%) | 3 (75%, 20/200 or worse) | NA | 12; 50 |
a This number was calculated by the authors of the present study from the numbers reported in the published study.